Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.
Follow PEN
Penumbra, Inc. (PEN) P/E ratio
As of 16 October 2026, Penumbra, Inc. (PEN) trades at a P/E ratio of 78.4×. Over the past ten years it has ranged from 0.0× (March 2023) to 2,127× (June 2023); the current reading is higher than 40% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 68.0× | (89.40%) |
| FY2024 | 642× | 516.22% |
| FY2023 | 104× | — |
| FY2022 | 0.0× | — |
| FY2021 | 1,915× | — |
| FY2020 | 0.0× | — |
| FY2019 | 117× | (81.76%) |
| FY2018 | 643× | (9.52%) |
| FY2017 | 711× | 438.39% |
| FY2016 | 132× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 77.2× | 2.97% |
| Mar 2026 | 75.0× | 10.20% |
| Dec 2025 | 68.0× | 13.87% |
| Sep 2025 | 59.7× | (10.83%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRKR Bruker Corporation compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| GMED Globus Medical, Inc. compare | 19.3× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 23.0× |
| PODD Insulet Corporation compare | 26.4× |
| SNN Smith & Nephew SNATS, Inc. compare | 35.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 42.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 43.7× |
| PEN Penumbra, Inc. | 78.4× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)